MedWatch

Novo Nordisk says US Inflation Reduction Act will hurt innovation

The new legislation meant to lower drug costs in the US, among other things, will actually end up restricting access to treatments, warns the Danish drugmaker.

US President Joe Biden has taken up the fight against high drug prices in the US | Photo: Mandel Ngan/AFP/Ritzau Scanpix

Novo Nordisk is in firm opposition to new legislation in the US, the Inflation Reduction Act, which among other things enables the US national health insurance program, Medicare, to negotiate and lower drug prices, reports Danish financial media Finans.

With new powers coming into effect in 2026, Medicare can require drugmakers to pay rebates should companies raise drug prices faster than inflation. An increasing variety of drugs could be affected by the law, including Novo Nordisk’s blockbuster diabetes drug, Ozempic, Danish business media Finans cites Financial Times reporting.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs